This article is more than 5 years old. Information may no longer be current.

TCT announces late-breaking science presentations

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Antithrombotic therapy after drug-eluting stent implantation in patients with atrial fibrillation, 1-month dual antiplatelet therapy after polymer-free DES implantation and a trial comparing transcatheter valve types and anesthesia approaches in aortic valve replacement are among the late-breaking presentations announced for Transcatheter Cardiovascular Therapeutics 2018.

TCT announced 15 late-breaking trials and 12 late-breaking clinical science studies will be presented at the meeting, which will be held Sept. 21-25 in San Diego.

The late-breaking trials announced include:

• COAPT, a randomized trial of transcatheter mitral valve leaflet approximation in patients with HF and secondary mitral regurgitation;
• IMPERIAL, a randomized trial of DES used to treat femoropopliteal lesions;
• LEADERS FREE II, which evaluated a polymer-free DES with 1 month of DAPT in patients at high bleeding risk;
• OAC ALONE, a randomized trial of oral anticoagulation with or without single antiplatelet therapy in patients with AF beyond 1 year after stent implantation;
• RADIOSOUND-HTN, a three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension;
• SOLVE-TAVI, a 2x2 trial comparing self-expanding valves with balloon-expandable valves and local anesthesia vs. general anesthesia in patients undergoing TAVR; and
• ULTIMATE, a randomized trial of IVUS guidance during coronary DES implantation.

Among the late-breaking clinical science presentations are:

• CorMicA, a trial dealing with invasive coronary function testing in patients with angina and nonobstructive CAD;
• FAST-FFR, an assessment of the accuracy of fractional flow reserve derived from coronary angiography;
• MAIN-COMPARE, a 10-year nonrandomized comparison of DES vs. bypass surgery in patients with left main disease; and
• PARTNER VALVE-IN-VALVE, a study of late follow-up after treatment of failed surgical aortic valves with a balloon-expandable transcatheter valve.

Cardiology Today’s Intervention and Healio.com will be on-site in San Diego to bring the latest in cutting-edge science from TCT. Visit Healio.com/Intervention for late-breaking science results, expert perspectives and more.